Smec Co.,Ltd (KOSDAQ:099440)
South Korea · Delayed Price · Currency is KRW 3,560.00
-20.00 (-0.56%)
At close: Aug 7, 2025, 3:30 PM KST
Verve Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | 2011 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '20 Jun 30, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | 2011 - 2015 |
Operating Revenue | 104,793 | 136,978 | 133,719 | 161,130 | 122,782 | 122,037 | Upgrade |
Other Revenue | 0 | - | - | - | 0 | - | Upgrade |
| 104,793 | 136,978 | 133,719 | 161,130 | 122,782 | 122,037 | Upgrade | |
Revenue Growth (YoY) | -31.19% | 2.44% | -17.01% | 31.23% | 0.61% | -9.11% | Upgrade |
Cost of Revenue | 97,840 | 122,565 | 107,939 | 133,628 | 98,556 | 98,495 | Upgrade |
Gross Profit | 6,953 | 14,413 | 25,779 | 27,502 | 24,225 | 23,542 | Upgrade |
Selling, General & Admin | 14,717 | 17,378 | 20,243 | 16,198 | 14,272 | 13,610 | Upgrade |
Research & Development | 4,994 | 5,246 | 4,662 | 4,323 | 4,797 | 4,440 | Upgrade |
Other Operating Expenses | 151.68 | 203.82 | 267.1 | 107.6 | 92.5 | 78.9 | Upgrade |
Operating Expenses | 27,940 | 29,176 | 26,421 | 22,787 | 20,044 | 19,245 | Upgrade |
Operating Income | -20,988 | -14,763 | -641.81 | 4,715 | 4,182 | 4,296 | Upgrade |
Interest Expense | -3,653 | -3,715 | -2,751 | -3,099 | -3,243 | -2,808 | Upgrade |
Interest & Investment Income | 321.13 | 263.02 | 236.79 | 254.46 | 206.56 | 210.47 | Upgrade |
Currency Exchange Gain (Loss) | 1,857 | 1,467 | 664.32 | -2,897 | 892.27 | 1,615 | Upgrade |
Other Non Operating Income (Expenses) | -2,394 | -3,766 | 710.65 | 1,795 | -119.85 | 444.9 | Upgrade |
EBT Excluding Unusual Items | -24,857 | -20,514 | -1,781 | 768.57 | 1,917 | 3,759 | Upgrade |
Gain (Loss) on Sale of Assets | -9.36 | 21.39 | 0.67 | 578.74 | 0.84 | -5 | Upgrade |
Asset Writedown | -508.12 | -508.12 | -332.25 | -1,170 | - | -16.91 | Upgrade |
Other Unusual Items | 888.49 | 60.77 | - | - | - | - | Upgrade |
Pretax Income | -24,486 | -20,940 | -2,113 | 177.68 | 1,918 | 3,737 | Upgrade |
Income Tax Expense | -3,102 | -3,953 | -437.91 | -156.59 | -53.39 | 371.37 | Upgrade |
Net Income | -21,384 | -16,987 | -1,675 | 334.27 | 1,971 | 3,365 | Upgrade |
Net Income to Common | -21,384 | -16,987 | -1,675 | 334.27 | 1,971 | 3,365 | Upgrade |
Net Income Growth | - | - | - | -83.05% | -41.42% | 122.59% | Upgrade |
Shares Outstanding (Basic) | 26 | 25 | 25 | 24 | 21 | 20 | Upgrade |
Shares Outstanding (Diluted) | 26 | 25 | 25 | 24 | 21 | 21 | Upgrade |
Shares Change (YoY) | -24.62% | -0.13% | 5.92% | 15.05% | -1.34% | 57.21% | Upgrade |
EPS (Basic) | -832.13 | -672.52 | -66.23 | 14.00 | 95.00 | 165.00 | Upgrade |
EPS (Diluted) | -832.60 | -673.00 | -66.23 | 14.00 | 95.00 | 160.00 | Upgrade |
EPS Growth | - | - | - | -85.26% | -40.63% | 41.59% | Upgrade |
Free Cash Flow | 3,214 | -15,596 | -14,437 | 1,990 | 6,859 | -9,247 | Upgrade |
Free Cash Flow Per Share | 125.07 | -617.45 | -570.85 | 83.34 | 330.54 | -439.64 | Upgrade |
Gross Margin | 6.64% | 10.52% | 19.28% | 17.07% | 19.73% | 19.29% | Upgrade |
Operating Margin | -20.03% | -10.78% | -0.48% | 2.93% | 3.41% | 3.52% | Upgrade |
Profit Margin | -20.41% | -12.40% | -1.25% | 0.21% | 1.61% | 2.76% | Upgrade |
Free Cash Flow Margin | 3.07% | -11.39% | -10.80% | 1.23% | 5.59% | -7.58% | Upgrade |
EBITDA | -15,862 | -9,565 | 3,835 | 9,544 | 8,971 | 8,422 | Upgrade |
EBITDA Margin | -15.14% | -6.98% | 2.87% | 5.92% | 7.31% | 6.90% | Upgrade |
D&A For EBITDA | 5,125 | 5,198 | 4,477 | 4,828 | 4,790 | 4,126 | Upgrade |
EBIT | -20,988 | -14,763 | -641.81 | 4,715 | 4,182 | 4,296 | Upgrade |
EBIT Margin | -20.03% | -10.78% | -0.48% | 2.93% | 3.41% | 3.52% | Upgrade |
Effective Tax Rate | - | - | - | - | - | 9.94% | Upgrade |
Advertising Expenses | - | 329.11 | 115.61 | 46.27 | 163.98 | 101.67 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.